Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Parliament Lead on Clinical Trials Regulation gets tough on transparency

This article was originally published in Scrip

Executive Summary

The lead legislator on the proposed Clinical Trials Regulation at the European Parliament has called for major transparency-related changes to be made to the draft legislation. Glenis Willmott has suggested, among other things, that the proposed text of the CTR be amended to clarify that "clinical trial data should not be considered commercially confidential once a marketing authorization has been obtained [by a drug company]".




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts